ライフサイエンスコーパス: NT-proBNP

1 NT-proBNP <=1,000 pg/ml by 90 days was associated with l

2 NT-proBNP (N-terminal pro brain natriuretic peptide) lev

3 NT-proBNP (N-terminal pro-B-type natriuretic peptide) al

4 NT-proBNP (N-terminal pro-B-type natriuretic peptide) wa

5 NT-proBNP (N-terminal pro-brain-type natriuretic peptide

6 NT-proBNP and IL-6 (but not cystatin C) were more strong

7 NT-proBNP concentrations among patients treated with sac

8 NT-proBNP geometric mean decreased by 53% in the pooled

9 NT-proBNP provides prognostic information beyond a conve

10 NT-proBNP was independently associated with all-cause mo

11 NT-proBNP was measured at regular intervals in GRIPHON.

12 CI, 1.33-1.49) per 1 SD increase, P<0.0001; NT-proBNP, 1.45 (1.36-1.54); P<0.0001.

13 elta = 60 m; 95% CI: 40 to 80 m; p < 0.001), NT-proBNP decreased (Delta = -25%; 95% CI: -38% to -9%;

14 k of morbidity/mortality events across all 3 NT-proBNP categories in both the baseline and time-depen

15 We analyzed patients using 4 NT-proBNP bands: <400, 400 to 999 (reference), 1000 to 1

16 egorized patients with and without AF into 5 NT-proBNP bands: <400, 400 to 999 (reference), 1000 to 1

17 Adding NT-proBNP values to the CSRS did not significantly impro

18 from including middle-aged adults and adding NT-proBNP and IL-6 as intermediate outcomes.

19 ifference in average 6- and 12-week adjusted NT-proBNP with dapagliflozin versus placebo (1133 pg/dL

20 Greater admission NT-proBNP concentration was associated with lower discha

21 In follow-up, among PHIV, a higher admission NT-proBNP concentration was associated with increased ca

22 Cox regression analysis, in addition to age, NT-proBNP serum levels, and RV size.

23 dless of elevated baseline concentration, an NT-proBNP <=1,000 pg/ml at 90 days was associated with b

24 Patients were randomized to either an NT-proBNP-guided strategy or usual care.

25 hospitalization or equivalent) to either an NT-proBNP-guided strategy or usual care.

26 A total of 198 (31.0%) subjects had an NT-proBNP <=1,000 pg/ml at 90 days with no difference in

27 that the guidance of HF therapy to reach an NT-proBNP reduction of >30% after clinical stabilization

28 nce interval (CI) 1.17, 5.03]; p = 0.02) and NT-proBNP (>=300 pg/mL; HR 2.28 [95% CI 1.24, 4.29]; p =

29 ialdehyde (-27% versus +5% versus +26%), and NT-proBNP(-26% versus -13.6% versus 9.1%) and increase o

30 ; hazard ratio, 1.24 [95% CI, 1.1-1.39]) and NT-proBNP (N-terminal pro-B-type natriuretic peptide; ha

31 between circulating IL6 (interleukin-6) and NT-proBNP (N terminal pro B-type natriuretic peptide) le

32 fe and significantly improved QOL, 6MHW, and NT-proBNP.

33 rdiographic findings, hemodynamics, 6MWD and NT-proBNP at baseline, and unadjusted analysis showed th

34 Increases in both BNP and NT-proBNP during 8 to 10 weeks of sacubitril/valsartan w

35 BNP and NT-proBNP were measured before and after 4 to 6 weeks, 8

36 BNP and NT-proBNP were measured simultaneously at screening and

37 icantly improved QOL, exercise capacity, and NT-proBNP.

38 infection in relation to plasma hs-cTnT and NT-proBNP concentrations among participants without prev

39 e outcomes in patients with high hs-cTnT and NT-proBNP levels.

40 ticipants without prevalent CVD, hs-cTnT and NT-proBNP were independently associated with infection r

41 Thus, hs-cTnT and NT-proBNP were independently associated with infection r

42 Relationships with ECV, hs-cTnT, and NT-proBNP were examined separately and as a composite wi

43 of life scores, 6-minute walk distance, and NT-proBNP (N-terminal pro-B-type natriuretic peptide; P<

44 een 2005 and 2016 in whom echocardiogram and NT-proBNP were both available at the time of admission.

45 tic resonance (CMR) measures of fibrosis and NT-proBNP levels in the MESA (Multi-Ethnic Study of Athe

46 eart failure including ejection fraction and NT-proBNP.

47 r ambulatory blood pressure, hematocrit, and NT-proBNP (N-terminal pro b-type natriuretic peptide).

48 s of IGF1 and increased levels of IGFBP1 and NT-proBNP were associated with higher risk of incident A

49 HF, where clinical assessment, imaging, and NT-proBNP may not be definitive, especially in HFpEF.

50 sensitivity cardiac troponin-T) <6 ng/L and NT-proBNP (N-terminal pro-B-type natriuretic peptide) <1

51 vels by 0.5 ng/L (CI, -0.9 to -0.1 ng/L) and NT-proBNP levels by 0.3 pg/mL (CI, -0.5 to -0.04 pg/mL).

52 by 0.5 ng/L (95% CI, -0.9 to -0.2 ng/L) and NT-proBNP levels by 0.3 pg/mL (CI, -0.5 to -0.1 pg/mL).

53 ded 6-minute walk test, quality-of-life, and NT-proBNP (N-terminal pro-brain natriuretic peptide).

54 trophil gelatinase-associated lipocalin) and NT-proBNP (N-terminal pro-B-type natriuretic peptide; al

55 A level of BNP <40 pg/mL and NT-proBNP <125 pg/mL allowed identifying patients withou

56 Both BNP (B-type natriuretic peptide) and NT-proBNP (N-terminal pro B-type natriuretic peptide) ar

57 nd biomarkers (high-sensitive troponin-T and NT-proBNP [N-terminal Pro-B-type natriuretic peptide]) a

58 udy the associations of dialysis vintage and NT-proBNP with all-cause mortality.

59 c output, cardiac index, atrial volumes, and NT-proBNP were also seen in the AVF closure group ( P<0.

60 ted in a similar decrease in body weight and NT-proBNP.

61 We also assayed NT-proBNP (N-terminal pro-B-type natriuretic peptide), h

62 nge in ANP, MR-proANP, BNP (using 5 assays), NT-proBNP (3 assays), proBNP(1-108), and CNP were measur

63 re included who were alive and had available NT-proBNP results 90 days after randomization.

64 tion model included age (A), biomarkers (B) (NT-proBNP, hs-cTnT, and low-density lipoprotein choleste

65 Background NT-proBNP (N-terminal pro-B-type natriuretic peptide) is

66 d a significant negative correlation between NT-proBNP and GMD in the medial and posterior cingulate

67 proBNP >=400 pg/mL, the relationship between NT-proBNP and outcomes differs with lower absolute risk

68 We examined the relationship between NT-proBNP and outcomes in patients with HF and preserved

69 Relationships between NT-proBNP (N-terminal Pro-B-type natriuretic peptide), s

70 rs and outcomes showed relationships between NT-proBNP and large-artery atherosclerotic stroke, IGFBP

71 ive postoperative cardiac injury biomarkers (NT-proBNP, H-FABP, hs-cTnT, and cTnI) strongly associate

72 N-terminal pro-BNP (NT-proBNP), copeptin (CT-proAVP), and miRNA expression p

73 nal pro-ANP (MR-proANP), N-terminal pro-BNP (NT-proBNP), proBNP(1-108), or C-type natriuretic peptide

74 BNP, NT-proBNP, hs-cTnT and hs-cTnI concentrations were measu

75 BNP, NT-proBNP, hs-cTnT, and hs-cTnI concentrations provide u

76 BNP, NT-proBNP, hs-cTnT, and hs-cTnI cut-offs, achieving pre-

77 BNP, NT-proBNP, hs-cTnT, and hs-cTnI were significantly highe

78 ort of 249 consecutive patients who had BNP, NT-proBNP, and TnI drawn simultaneously to create the st

79 The prognostic accuracy of BNP, NT-proBNP, hs-cTnI, and hs-cTnT for MACE was moderate-to

80 e diagnostic and prognostic accuracy of BNP, NT-proBNP, hs-cTnT, and hs-cTnI concentrations, alone an

81 Combining BNP/NT-proBNP with hs-cTnT/hs-cTnI further improved diagnost

82 The BNP/NT-proBNP criteria were not different for patients in at

83 NP, aminoterminal proBNP (NT-proBNP), or BNP:NT-proBNP ratio.

84 ransferase 4 gene GALNT4 associated with BNP:NT-proBNP ratio but not with BNP or midregional proANP,

85 nt (composite morbidity/mortality events) by NT-proBNP category at baseline using Cox proportional-ha

86 ged and standardized measures of cystatin C, NT-proBNP (N-terminal pro-B-type natriuretic peptide), i

87 Cystatin C, NT-proBNP, and IL-6 (but not E-selectin) were inversely

88 city and augmentation index, (4) circulating NT-proBNP (N-terminal pro-B-type natriuretic peptide), T

89 ction in men led to increases in circulating NT-proBNP, which were attenuated by testosterone replace

90 In comparison, NT-proBNP is not a substrate of neprilysin inhibition, a

91 In conclusion, NT-proBNP and RVSP were independently predictive in HFpE

92 V with HF had higher admission and discharge NT-proBNP levels, and less change in NT-proBNP concentra

93 mmation (i.e., CRP), cardiac function (i.e., NT-proBNP), and cardiac necrosis (i.e., Troponin T).

94 s well as glomerular filtration rate (eGFR), NT-proBNP, interleukin-6 and high-sensitive CRP as covar

95 lity, 405 patients were randomized to either NT-proBNP-guided or conventional treatment (1:1).

96 Elevated NT-proBNP (>14 pmol/L), elevated high-sensitive troponin

97 vity cardiac troponin T; 17.7% with elevated NT-proBNP) with 825 incident CV events over 10-year foll

98 HFpEF) as classified by a guideline-endorsed NT-proBNP ruleout threshold, were correctly reclassified

99 For NT-proBNP, higher increases from baseline were seen in p

100 pg/mL and HR = 1.19 (95% CI: 1.06, 1.34) for NT-proBNP 137.2-248.0 pg/mL vs. <48.1 pg/mL).

101 iac troponin I, 1.65 (95% CI, 1.12-2.44) for NT-proBNP, and 1.65 (95% CI, 1.13-2.41) for high-sensiti

102 % for BNP and C-statistics of 64% to 70% for NT-proBNP) with no difference between the 2 biomarkers.

103 placebo were -15.0%, -16.1%, and -26.8% for NT-proBNP, and -8.3%, -11.9%, and -10.0% for hsTnI at we

104 <3 ng/L; HR = 1.57 (95% CI: 1.35, 1.81) for NT-proBNP >=248.1 pg/mL and HR = 1.19 (95% CI: 1.06, 1.3

105 .96, specificity 0.91, and accuracy 0.90 for NT-proBNP alone to corresponding metrics of 0.99, 0.99,

106 st significance after further adjustment for NT-proBNP (HR, 1.14; 0.96-1.34; P = 0.14).

107 ide of the hospital (178 versus 179 days for NT-proBNP versus conventional patients, P=0.39).

108 nd right atrial areas, LV ejection fraction, NT-proBNP (N-terminal pro-B-type natriuretic peptide) le

109 therapy intensification relative to the goal NT-proBNP value of 1,000 pg/ml explored in the GUIDE-IT

110 Greater NT-proBNP concentration was associated with lower Barthe

111 (representing most patients in each group), NT-proBNP had similar predictive value for adverse cardi

112 .5 mg or 25 mg daily) spironolactone and had NT-proBNP levels of 1000 pg/mL or more or B-type natriur

113 vel, in comparison with patients with a high NT-proBNP level.

114 t the relevance of the low, medium, and high NT-proBNP categories as part of the multiparametric risk

115 egorized post hoc into low, medium, and high NT-proBNP subgroups according to 2 independent sets of t

116 with diastolic dysfunction, anemia, and high NT-proBNP.

117 tural log IL6 was associated with 16% higher NT-proBNP level ([95% CI, 10%-22%]; P=0.002).

118 log IL6 level also associated with 6% higher NT-proBNP level ([95% CI, 1%-11%]; P=0.02) at 4-year fol

119 Results A higher NT-proBNP level was associated with smaller total brain

120 In adjusted analyses, higher NT-proBNP levels were less predictive of HF hospitalizat

121 nts who were older, were male, or had higher NT-proBNP.

122 -proBNP concentrations; in follow-up, higher NT-proBNP levels among PHIV were associated with cardiov

123 lower CD4 count were associated with higher NT-proBNP concentrations.

124 aseline high-sensitivity troponin T (hsTnT), NT-proBNP (N-terminal B-type natriuretic peptide), and g

125 ior stroke/transient ischemic attack, hsTnT, NT-proBNP) and ABC-bleeding (age, prior bleeding, hemogl

126 Median baseline hsTnT, NT-proBNP, and GDF-15 levels were 13.7 ng/L (25th-75th p

127 Elevated hsTnT, NT-proBNP, and GDF-15 were independently associated with

128 ratio, high-sensitivity cardiac troponin I, NT-proBNP (N-terminal pro-B-type natriuretic peptide), o

129 l selection from each cluster, we identified NT-proBNP (standard hazard ratio [95%CI] = 1.56 [1.17-2.

130 n SBP was directly associated with change in NT-proBNP (p < 0.001) but not KCCQ-OSS (p = 0.40).

131 italization for heart failure, and change in NT-proBNP [N-terminal pro-B-type natriuretic peptide]),

132 scharge NT-proBNP levels, and less change in NT-proBNP concentrations.

133 The primary end point was the change in NT-proBNP levels from baseline to 96 hours.

134 8]; P(interaction)<0.001), with no change in NT-proBNP levels.

135 Longitudinal changes in NT-proBNP (N-terminal pro-B-type natriuretic peptide), c

136 and lower admission-to-discharge changes in NT-proBNP levels (32 vs 48%, respectively; P = .007).

137 NT-proBNP concentrations and the changes in NT-proBNP levels between PHIV with HF and uninfected con

138 as greater fluid loss (P=0.001), decrease in NT-proBNP (N-terminal pro-B-type natriuretic peptide; P=

139 The absolute decrease in NT-proBNP at 4 months was inversely correlated with base

140 s, suggested that a predischarge decrease in NT-proBNP level was associated with lower risk for the c

141 verall summary score, or a >=20% decrease in NT-proBNP.

142 n z score per standard deviation increase in NT-proBNP level, -0.021; 95% confidence interval [CI]: -

143 n z score per standard deviation increase in NT-proBNP level, -0.037; 95% CI: -0.057, -0.017; P < .00

144 In contrast, such striking increases in NT-proBNP following the use of the neprilysin inhibitor

145 3, 95% CI 0.98-3.05), and >=20% reduction in NT-proBNP (44.0 vs 29.4%, adjusted OR 1.9, 95% CI 1.1-3.

146 s associated with a significant reduction in NT-proBNP and cTnI, suggesting improvement in myocardial

147 ated with sacubitril-valsartan, reduction in NT-proBNP concentration was weakly yet significantly cor

148 nstrated a significant (P=0.04) reduction in NT-proBNP serum levels (-250 [-1465; 33] pg/mL; relative

149 S/V was associated with similar reduction in NT-proBNP, improvement in health status, and reverse rem

150 variables and cardiac biomarkers (including NT-proBNP [N-terminal pro-B-type natriuretic peptide]).

151 th decreased ejection fraction and increased NT-proBNP in wide brain regions including the whole fron

152 Following S/V initiation, NT-proBNP decreased in all 3 groups (P<0.0001) associate

153 concentration ranges for CRP (0.1-50 mg/L), NT-proBNP (50-10,000 pg/mL), cTnI (1-10,000 pg/mL), and

154 natriuretic peptide) was 124 (69-197) ng/L, NT-proBNP (N-terminal-pro-B-type natriuretic peptide) 62

155 rt Association class III/IV, RVESRI, and log NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) we

156 del, each 1-SD increment (0.44 pg/ml) of log NT-proBNP was associated with a 0.62% increment in extra

157 performed to examine the association of log NT-proBNP with CMR T1 mapping indices.

158 At 12 months, the change in log2-NT-proBNP concentration was correlated with changes in L

159 was the correlation between changes in log2-NT-proBNP concentrations and left ventricular (LV) EF, L

160 For example, a 1-SD increase in logged NT-proBNP was associated with weaker grip (-0.63 kg, 95%

161 efit of selexipag seen in the medium and low NT-proBNP subgroups (interaction P values 0.20 and 0.007

162 terone dose was associated with a 4.3% lower NT-proBNP at follow-up (95% confidence interval: -7.9% t

163 ients, Black and Hispanic patients had lower NT-proBNP (g=0.34) and differences between groups in bas

164 ut or those without without AF in the lowest NT-proBNP band (<400 pg/mL; 8.0 versus 3.2 per 100 patie

165 Dual primary outcomes were (1) mean NT-proBNP (N-terminal pro b-type natriuretic peptide) an

166 agliflozin over 12 weeks did not affect mean NT-proBNP but increased the proportion of patients exper

167 acute HF, independent of repeatedly measured NT-proBNP.

168 echocardiography, and biomarker measurement (NT-proBNP, high-sensitive troponin-T, and growth-differe

169 Median NT-proBNP value was elevated (910 pg/mL), and right vent

170 ferent (all favoring digoxin), with a median NT-proBNP level of 960 pg/mL (interquartile range, 626 t

171 his was accompanied by an increase in median NT-proBNP (+8 pg/ml; p = 0.02).

172 In the lipopolysaccharide study, median NT-proBNP levels rose from 21 pg/mL pre-lipopolysacchari

173 The median NT-proBNP concentration at baseline was 816 pg/mL (inter

174 xipag-treated patients with a low and medium NT-proBNP level, and 90% and 56% lower in placebo-treate

175 acebo-treated patients with a low and medium NT-proBNP level, in comparison with patients with a high

176 Nonetheless, NT-proBNP-guided therapy did not significantly improve t

177 less or an amino-terminal pro-brain-type NP (NT-proBNP) decrease of at least 30%.

178 althy participants, we found that B-type-NP, NT-proBNP (N-terminal-pro-B-type NP), and MRproANP (midr

179 90 days with no difference in achievement of NT-proBNP goal between the biomarker-guided and usual ca

180 We evaluated the association of NT-proBNP concentration with disease severity, discharge

181 rovide first evidence for the association of NT-proBNP level and treatment response.

182 ostic importance of a given concentration of NT-proBNP in HF patients with and without AF.

183 The median baseline concentration of NT-proBNP was 2067 (Q1, Q3: 1217-4003) and BNP 318 (Q1,

184 Among PHIV, each doubling of NT-proBNP was associated with a 19% increased risk of de

185 1.31 (95% CI: 1.02 to 1.68) per doubling of NT-proBNP.

186 tril/Valsartan Versus Enalapril on Effect of NT-proBNP in Patients Stabilized From an Acute Heart Fai

187 ion fraction <=40% and a modest elevation of NT-proBNP (N-terminal pro-B-type natriuretic peptide) we

188 lar ejection fraction <=40% and elevation of NT-proBNP (N-terminal pro-B-type natriuretic peptide), w

189 AV loop placement causes serum elevations of NT-proBNP, copeptin as well as specific circulating miRN

190 at 6 hours after reperfusion, the levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) by

191 ation (AF) have higher circulating levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) th

192 reater reductions from baseline in levels of NT-proBNP (P=0.017) and BNP (P=0.002); these differences

193 and vascular risk factors, higher levels of NT-proBNP (RR, 3.19; 95% CI, 2.62-3.90) and hs-cTnT (RR,

194 Higher levels of NT-proBNP may identify those in midlife at risk of accel

195 Median (Q1-Q3) levels of NT-proBNP were 1286 pg/mL (778-2072) in those with AF an

196 Median (Q1, Q3) levels of NT-proBNP were 1817 pg/mL (1095-3266 pg/mL) in those wit

197 Elevated levels of NT-proBNP, high-sensitive troponin-T, and growth-differe

198 abnormalities were correlated with levels of NT-proBNP, hs-cTnT, CRP, or oxidative stress biomarkers.

199 udy was to examine the prognostic meaning of NT-proBNP changes following heart failure (HF) therapy i

200 Serial measurement of NT-proBNP testing was discouraged in the usual care grou

201 The ratio of NT-proBNP to BNP in heart failure and reduced ejection f

202 urther establish the prognostic relevance of NT-proBNP levels in PAH and provide first evidence for t

203 Routine use of NT-proBNP for ED syncope prognostication is not recommen

204 Before considering the use of NT-proBNP for risk stratification, further research shou

205 However, data supporting the use of NT-proBNP risk thresholds in assessing prognosis in PAH

206 pportunity to assess the prognostic value of NT-proBNP thresholds in a controlled clinical trial and

207 ognostication, but many centers do not offer NT-proBNP.

208 >=75 years, male sex, CHADS(2) score >2, or NT-proBNP (N-terminal pro-B-type natriuretic peptide) >=

209 Combining BNP or NT-proBNP levels and echocardiographic parameters should

210 ons without CVD but with elevated hs-cTnT or NT-proBNP levels should be recognized to have similar in

211 e prevalent CVD but had hs-cTnT >=14 ng/L or NT-proBNP >=248.1 pg/mL.

212 ization within 12 months, BNP >=100 pg/mL or NT-proBNP >=400 pg/mL).

213 ted natriuretic peptides: BNP >=150 pg/mL or NT-proBNP >=600 pg/mL (for patients with HF hospitalizat

214 pathy Questionnaire overall summary score or NT-proBNP, 61.5% of dapagliflozin-treated patients met t

215 vated high-sensitivity cardiac troponin T or NT-proBNP had a 10-year CV incidence rate of 11.0% and 4

216 ns in high-sensitivity cardiac troponin T or NT-proBNP identify individuals with elevated BP or hyper

217 with artificial intelligence and outperforms NT-proBNP.

218 aphy, independent of the natriuretic peptide NT-proBNP, kidney function and of markers of systemic in

219 d N-terminal pro-B-type natriuretic peptide (NT-proBNP) >=300 pg/ml.

220 se N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac troponins T and I (TnT and TnI) f

221 s N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (cTnT

222 N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-c

223 m N-terminal-pro-B-type natriuretic peptide (NT-proBNP) and total testosterone levels were measured a

224 r N-terminal pro-B-type natriuretic peptide (NT-proBNP) are at high risk of infection is unknown.

225 in N-terminal pro-brain natriuretic peptide (NT-proBNP) by after therapy.

226 h N-terminal pro-B-type natriuretic peptide (NT-proBNP) clearly improved specificity and accuracy fro

227 e N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline through weeks 4 a

228 d N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration predicts poor prognosis of non-

229 ino-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations among PHIV with HF has not bee

230 s N-terminal pro-b-type natriuretic peptide (NT-proBNP) concentrations.

231 re N-terminal pro-brain natriuretic peptide (NT-proBNP) in human serum within its clinical range.

232 m N-terminal pro-B-type natriuretic peptide (NT-proBNP) is considered a marker that is expressed in r

233 or N-terminal pro-brain natriuretic peptide (NT-proBNP) level, an elevated E/A ratio (1.5 vs. 1.0; P

234 n N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels compared with usual care alone.

235 a N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and health status as assessed by Kans

236 ted N-terminal probrain natriuretic peptide (NT-proBNP) levels.

237 d N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.

238 ino-terminal pro-B-type natriuretic peptide (NT-proBNP) was not superior to GDMT alone.

239 ) and N-terminal B-type natriuretic peptide (NT-proBNP) were measured using serum samples acquired an

240 nal prohormone of brain natriuretic peptide (NT-proBNP)) and a measure of functional status (such as

241 , N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity C-reactive protein (hs-

242 , N-terminal pro b-type natriuretic peptide (NT-proBNP), cardiac troponin I (cTnI), and fibrinogen- w

243 f N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitive troponin-T, and growth-differ

244 m N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity troponin I (hsTnI), soluble

245 s N-terminal pro B-type natriuretic peptide (NT-proBNP), urine output (UOP), and plasma creatinine.

246 d N-terminal pro-B-type natriuretic peptide (NT-proBNP).

247 d N-terminal pro-B-type natriuretic peptide (NT-proBNP).

248 (N-terminal pro-B-type natriuretic peptide [NT-proBNP] >=100 pg/mL) can inform cardiovascular (CV) r

249 nd N-terminal pro-brain natriuretic peptide [NT-proBNP] level) at 6 months, 20 end points at 12 month

250 nal prohormone of brain natriuretic peptide [NT-proBNP]) to predict baseline susceptibility to develo

251 N-terminal pro-B-type natriuretic peptides (NT-proBNP) has been preferred and recommended.

252 riuresis, lower arterial pressure and plasma NT-proBNP.

253 We measured plasma NT-proBNP on arrival at the hospital before kidney trans

254 structions for use (enrollment criteria plus NT-proBNP <1,600 pg/ml), consisted of 245 patients follo

255 e decompensated HF treatment by a predefined NT-proBNP target (>30% reduction from admission to disch

256 siderable part by variation in pretransplant NT-proBNP at the time of transplantation.

257 We want to study whether pretransplant NT-proBNP is associated with posttransplantation mortali

258 Concentrations of MR-proANP, NT-proBNP, and proBNP(1-108) variably declined after tre

259 oANP (MR-proANP), BNP, aminoterminal proBNP (NT-proBNP), or BNP:NT-proBNP ratio.

260 atriuretic Peptide (BNP), N-terminal proBNP (NT-proBNP), and high-sensitivity cardiac troponin (hs-cT

261 cant reductions in CRP (C-reactive protein), NT-proBNP (N-terminal pro-B-type natriuretic peptide), H

262 ionally, a core set of 5 shared HF proteins (NT-proBNP [N-terminal pro-B type natriuretic peptide], E

263 Sensitivity is calculated by quantifying NT-proBNP, a clinical biomarker of heart failure, in buf

264 Baseline median (interquartile range) NT-proBNP levels were 4601 (2697-9596) pg/mL among the g

265 with acute decompensated HF using a relative NT-proBNP target would lead to improved outcomes compare

266 dent HF (P<3.8x10(-)(5); 3 with higher risk: NT-proBNP [N-terminal proB-type natriuretic peptide], TS

267 Serum NT-proBNP and copeptin levels exceeded the upper referen

268 Serum NT-proBNP and cTnT levels correlated with increasing LGE

269 Serum NT-proBNP concentrations were significantly higher among

270 Serum NT-proBNP was measured locally at 1 site and batch proce

271 Although serum NT-proBNP concentrations were generally much higher amon

272 Both serum NT-proBNP and serum hsTnI levels increased in placebo re

273 age of 67.6 years) at 6 sites had both serum NT-proBNP measurements and CMR with T1 mapping of indice

274 In community-dwelling persons, higher serum NT-proBNP levels are associated with volumetric and micr

275 f 100 patients who were evaluated with serum NT-proBNP levels and echocardiography were included.

276 AV loop placement, with an especially strong NT-proBNP increase in patients with preexistent cardiac

277 The net reclassification index shows that NT-proBNP would have correctly reclassified 3% of patien

278 obtained a relationship between GMD and the NT-proBNP (N-terminal prohormone of brain natriuretic pe

279 We compared the NT-proBNP concentrations and the changes in NT-proBNP le

280 an therapy led to a greater reduction in the NT-proBNP concentration than enalapril therapy.

281 The time-averaged reduction in the NT-proBNP concentration was significantly greater in the

282 The greater reduction in the NT-proBNP concentration with sacubitril-valsartan than w

283 system will allow centers without access to NT-proBNP the ability to appropriately stage patients wi

284 In contrast to NT-proBNP (N-terminal pro-B-type natriuretic peptide) an

285 With both thresholds, baseline and follow-up NT-proBNP categories were highly prognostic for future m

286 0 ng/dl had a 26% higher predicted follow-up NT-proBNP than someone whose serum testosterone remained

287 adjusted analysis showed that only follow-up NT-proBNP was associated with all-cause hospitalization

288 hospitalizations; higher left atrial volume, NT-proBNP (N-terminal pro-B-type natriuretic peptide), a

289 When NT-proBNP was analyzed as a continuous variable, similar

290 ) 4 months after BMC administration, whereas NT-proBNP levels remained unchanged in patients in the 2

291 This study aimed to assess whether NT-proBNP-guided therapy of patients with acute decompen

292 These findings were consistent whether NT-proBNP was examined as a categorical or continuous va

293 failure with reduced ejection fraction whose NT-proBNP levels decreased to <=1,000 pg/ml during GDMT

294 ection fraction patients without AF and with NT-proBNP <400 pg/mL are low.

295 HIV, VLs and CD4 counts were associated with NT-proBNP concentrations; in follow-up, higher NT-proBNP

296 Multi-microRNA panels in combination with NT-proBNP are highly discriminatory and improved specifi

297 NGAL was further enhanced when combined with NT-proBNP or creatinine.

298 , and 0.68 in Validation 2, as compared with NT-proBNP alone of AUC 0.71, specificity 0.46, and accur

299 n the distribution of BNP when compared with NT-proBNP, but both peptides retained their prognostic a

300 Among patients with NT-proBNP >=400 pg/mL, the relationship between NT-proBN